Intest Res.  2024 Jul;22(3):387-388. 10.5217/ir.2024.00016.

Halitosis: an underestimated but important extraintestinal manifestation in inflammatory bowel disease

• Qian XX

• KMID: 2558198
• DOI: http://doi.org/10.5217/ir.2024.00016

Reference

1. Kim KW, Kang HW. Regional variations in the prevalence of primary sclerosing cholangitis associated with inflammatory bowel disease. Intest Res. 2023; 21:413–414.

2. Kim YS, Hurley EH, Park Y, Ko S. Treatment of primary sclerosing cholangitis combined with inflammatory bowel disease. Intest Res. 2023; 21:420–432.

3. Harbord M, Annese V, Vavricka SR, et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016; 10:239–254.

4. Tímár ÁE, Párniczky A, Budai KA, et al. Beyond the gut: a systematic review and meta-analysis of advanced therapies for inflammatory bowel disease-associated extraintestinal manifestations. J Crohns Colitis. 2024; 18:851–863.

5. Poniewierka E, Pleskacz M, Łuc-Pleskacz N, Kłaniecka-Broniek J. Halitosis as a symptom of gastroenterological diseases. Prz Gastroenterol. 2022; 17:17–20.

6. Kumar KM, Nachiammai N, Madhushankari GS. Association of oral manifestations in ulcerative colitis: a pilot study. J Oral Maxillofac Pathol. 2018; 22:199–203.

7. Aginbay A, Khamzina S, Zhanasbayeva M, Kaliaskarova K, Batyrbekov K, Kulkayeva G. Efficacy of infliximab for the treatment of oral manifestation of Crohn’s disease. Case Rep Gastroenterol. 2022; 16:629–636.

8. Qian J, Qian XX, Tian Y. Study on halitosis in patients with ulcerative colitis. Chin J Gastroenterol Hepatol. 2022; 3:316–322.